Praxis' Elsunersen Shows 77% Seizure Reduction in SCN2A DEE Trial
Event summary
- Praxis' elsunersen demonstrated a 77% placebo-adjusted seizure reduction in SCN2A DEE patients (p=0.015).
- 71% of treated patients achieved >50% seizure reduction by period 6, with sustained benefits observed for up to one year.
- 100% of elsunersen patients showed improvements in sleep, motor function, and attention, with no treatment-related adverse events reported.
- EMBRAVE Part A was a randomized, placebo-controlled Phase 1/2 trial involving 9 pediatric patients aged 2-12.
The big picture
Praxis' positive Phase 1/2 results for elsunersen mark a significant milestone in the treatment of SCN2A developmental and epileptic encephalopathy, a rare and severe neurological disorder. The data suggest elsunersen could be the first disease-modifying therapy for this condition, addressing both seizures and broader developmental symptoms. The company's collaboration with Ionis Pharmaceuticals and RogCon underscores the strategic importance of antisense oligonucleotide technology in precision neuroscience.
What we're watching
- Regulatory Pathway
- Whether the FDA and EMA will expedite elsunersen's approval given its Orphan Drug and PRIME designations.
- Clinical Validation
- The pace at which Praxis can replicate these results in the pivotal EMBRAVE3 study.
- Market Differentiation
- How elsunersen's disease-modifying potential positions Praxis against competitors in the SCN2A DEE space.
Related topics